Corton Capital Inc. Makes New $223,000 Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Corton Capital Inc. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 946 shares of the biopharmaceutical company’s stock, valued at approximately $223,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Cetera Investment Advisers raised its holdings in shares of Alnylam Pharmaceuticals by 66.3% during the fourth quarter. Cetera Investment Advisers now owns 4,770 shares of the biopharmaceutical company’s stock valued at $1,122,000 after purchasing an additional 1,902 shares during the last quarter. BOKF NA grew its position in shares of Alnylam Pharmaceuticals by 592.7% during the fourth quarter. BOKF NA now owns 381 shares of the biopharmaceutical company’s stock valued at $91,000 after purchasing an additional 326 shares in the last quarter. Bridger Management LLC increased its position in Alnylam Pharmaceuticals by 11.2% in the fourth quarter. Bridger Management LLC now owns 41,182 shares of the biopharmaceutical company’s stock worth $9,691,000 after purchasing an additional 4,160 shares during the last quarter. Brevan Howard Capital Management LP raised its position in Alnylam Pharmaceuticals by 3.4% during the fourth quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company’s stock valued at $314,000 after purchasing an additional 44 shares during the period. Finally, Captrust Financial Advisors lifted its holdings in shares of Alnylam Pharmaceuticals by 32.7% in the 4th quarter. Captrust Financial Advisors now owns 6,414 shares of the biopharmaceutical company’s stock worth $1,509,000 after acquiring an additional 1,581 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $276.55 on Thursday. The stock has a market capitalization of $36.06 billion, a price-to-earnings ratio of -127.44 and a beta of 0.17. Alnylam Pharmaceuticals, Inc. has a twelve month low of $144.73 and a twelve month high of $304.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The company has a 50-day simple moving average of $250.06 and a two-hundred day simple moving average of $254.80.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to analysts’ expectations of $584.32 million. Alnylam Pharmaceuticals’s revenue was up 20.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.16) earnings per share. Analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analysts Set New Price Targets

ALNY has been the subject of several recent research reports. Bank of America lifted their price objective on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a “buy” rating in a report on Friday, March 21st. HC Wainwright reissued a “buy” rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Needham & Company LLC reissued a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 9th. Royal Bank of Canada boosted their price objective on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an “outperform” rating in a research note on Friday, March 21st. Finally, Wells Fargo & Company boosted their price objective on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an “equal weight” rating in a research note on Friday, March 21st. One research analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $319.17.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the completion of the transaction, the chief executive officer now owns 81,526 shares of the company’s stock, valued at $20,802,989.42. The trade was a 1.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Jeffrey V. Poulton sold 967 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $246,749.39. Following the completion of the transaction, the chief financial officer now owns 32,786 shares in the company, valued at approximately $8,366,003.62. The trade was a 2.86 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 7,392 shares of company stock worth $1,875,627. Corporate insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.